ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill

 
• By Alaric DeArment
  
freezing
ICER's report said current evidence was inadequate to demonstrate a net health benefit for Merck/Ridgeback's Lagevrio versus symptomatic care • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip